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AUC0–168h by 25 %, with MK-0646 accumulation from 
the previous dose contributing to the observed increase. 
The co-administration of MK-0646 with cetuximab and 
irinotecan did not affect the PK of cetuximab and irinote-
can, but reduced the Cmax (from 16.8 to 13.0 ng/mL) and 
the AUC0–24h (by 13 %) of SN-38, the active metabolite of 
irinotecan.
Conclusions The triple combination of MK-0646, 
cetuximab, and irinotecan was well tolerated in Japanese 
patients with advanced colorectal cancer. These results 
indicate a minimal potential for PK interactions between 
MK-0646 and cetuximab and between MK-0646 and 
irinotecan/SN-38.
Keywords Colorectal cancer · MK-0646 · Anti-IGF-1R 
antibody · Pharmacokinetic interactions · Phase I study
Introduction
Colorectal cancer is the third most common cause of 
cancer-related death in both men and women worldwide. 
For patients with metastatic colorectal cancer, the standard 
of care using a fluoropyrimidine, irinotecan, oxaliplatin, 
and bevacizumab (in combination or sequentially) results 
in a median survival period of 18–21 months [1–4]. How-
ever, once these standard drugs have failed, further options 
are limited. Such patients with progressive metastatic dis-
ease, despite having received currently available first- and 
second-line chemotherapies, and who exhibit the tumor-
specific expression of the epidermal growth factor recep-
tor (EGFR) are eligible to receive third-line treatment with 
irinotecan and cetuximab. Cetuximab is a monoclonal anti-
body that specifically blocks EGFR, a member of the ErbB 
family of receptors [5]. EGFR is overexpressed in up to 
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Purpose The safety, tolerability, and pharmacokinetic 
(PK) interactions of MK-0646 in combination with cetuxi-
mab and irinotecan were investigated in Japanese patients 
with advanced colorectal cancer.
Methods Twenty patients were treated in the following 
study arms in combination with cetuximab and irinotecan: 
A [MK-0646 (10 mg/kg) weekly starting on Day 22], B 
[MK-0646 (15 mg/kg) on Day 8, followed by 7.5 mg/kg 
every 2 weeks], or C [MK-0646 (10 mg/kg) on Day 1 and 
weekly starting on Day 22]. Dose limiting toxicities (DLTs) 
were evaluated during a prespecified 4-week period in arms 
A and B. Full PK sampling was performed to evaluate the 
PK interactions.
Results One of the 6 evaluable patients in arm A devel-
oped a DLT (grade 3 hyperglycemia); no DLTs occurred 
in the 6 patients in arm B. Common treatment-related 
adverse events included leukopenia, neutropenia, derma-
titis acneiform, paronychia, nausea, stomatitis, diarrhea, 
and decreased appetite. The co-administration of cetuxi-
mab and irinotecan with MK-0646 increased the MK-0646 
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80 % of colorectal cancers and is associated with a poor 
survival outcome [6–8]. Despite treatment with cetuximab, 
the prognosis for patients in this population remains poor, 
with a response rate of 22.9 %, a median time to progres-
sion of 4.1 months, and a median overall survival period of 
8.6 months [9].
MK-0646 (dalotuzumab) is a humanized IgG1 kappa 
antibody targeting insulin-like growth factor receptor 
type 1 (IGF-1R). Signaling through IGF-1R mediates cell 
growth and proliferation as well as resistance to apoptosis 
in all major solid tumors, including colorectal cancer [10]. 
MK-0646 has two possible mechanisms of action: (1) the 
inhibition of IGF-1-mediated cell signaling, and (2) anti-
body-dependent, cell-mediated cytotoxicity (ADCC). A 
preclinical study suggested a synergistic effect on tumor 
growth inhibition when combined with either a chemother-
apeutic agent or an anti-EGFR antibody [10]. Additionally, 
emerging evidence suggests crosstalk between the EGFR 
and IGF-1R signaling pathways [11]. Hence, the concur-
rent inhibition of IGF-IR and EGFR provides a logical 
rationale for combining anti-IGF-IR and anti-EGFR strate-
gies in the treatment of cancer.
A phase I study of single-agent MK-0646 was conducted 
in patients with advanced solid tumors [12]. MK-0646 was 
generally well tolerated and exhibited dose-proportional 
pharmacokinetics (PKs). The safety and tolerability of a 
triple combination of MK-0646, cetuximab, and irinote-
can was evaluated in an open-labeled safety run-in prior 
to commencing a blinded randomized phase II/III study 
[13]. The results suggested that the triple combination of 
MK-0646, cetuximab, and irinotecan was tolerable, with no 
overlapping toxicities highlighted in non-Japanese patients 
with metastatic colorectal cancer.
In the present study, the safety, tolerability, and PK of 
MK-0646 in combination with cetuximab and irinote-
can in Japanese patients with advanced colorectal can-
cer were investigated. The potential for PK interactions 
between MK-0646 and cetuximab and between MK-0646 
and irinotecan as well as SN-38, the active metabolite of 
MK-0646, was assessed. The tumor response to this tri-




This study was conducted based on the Declaration of 
Helsinki and the Guidelines for the Clinical Evaluation 
Methods of Anti-Cancer Drugs in Japan (Japanese Min-
istry of Health, Labour, and Welfare notification, dated 
November 1, 2005). The study was approved by the insti-
tutional review board of each study site.
The main eligibility criteria were as follows: histologi-
cally (or cytologically) confirmed advanced colorectal can-
cer that had previously failed to respond to both irinotecan 
and oxaliplatin and had progressed on or within 3 months 
of the last therapy; a patient age of 20 years or older; an 
Eastern Cooperative Oncology Group performance status 
of 0 or 1; and adequate hematological, hepatic, and renal 
functions. The exclusion criteria included the use of chemo-
therapy, radiotherapy, or biological therapy within 4 weeks 
prior to enrollment; primary or unstable central nervous 
system metastasis; and symptomatic ascites or pleural effu-
sion requiring treatment. All the patients provided informed 
consent, and the trial was conducted in accordance with 
current good clinical practice standards. This trial was reg-
istered at ClinicalTrials.gov as NCT00925015.
Drug administration
In arm A, cetuximab at a dose of 400 mg/m2 was infused 
over 120 min as a loading dose on Day 1 of Cycle 1. On the 
following weeks, cetuximab at a dose of 250 mg/m2 was 
infused over 60 min once weekly as a maintenance dose. 
Irinotecan at a dose of 150 mg/m2 was infused over 90 min 
every other week. MK-0646 at a dose of 10 mg/kg was 
infused over 120 min once weekly starting on Day 22 of 
Cycle 1.
In arm B, cetuximab at a dose of 400 mg/m2 was infused 
over 120 min as a loading dose on Day 1 of Cycle 1. On 
subsequent weeks, cetuximab at a dose of 250 mg/m2 was 
infused over 60 min once weekly as a maintenance dose. 
Irinotecan was infused over 90 min according to the dos-
age and regimen that the patient had most recently received 
prior to enrollment in this study. MK-0646 was infused 
over 120 min once every other week starting on Day 8 of 
Cycle 1. The first infusion was a loading dose of 15 mg/
kg, while all subsequent infusions consisted of a dose of 
7.5 mg/kg.
In arm C, cetuximab at a dose of 400 mg/m2 was infused 
over 120 min as a loading dose on Day 8 of Cycle 1. On 
following weeks, cetuximab at a dose of 250 mg/m2 was 
infused over 60 min once weekly as a maintenance dose. 
Irinotecan was infused every other week over 90 min at a 
dose of 150 mg/m2 starting on Day 8 of Cycle 1. On Day 1 of 
Cycle 1, MK-0646 at a dose of 10 mg/kg was infused over 
120 min. On Day 22 (following a 2-week rest-period) and 
thereafter, MK-0646 was infused at a dose of 10 mg/kg 
over 120 min once weekly.
The study treatments were continued until the patient 
exhibited disease progression or the occurrence of an unac-
ceptable toxicity.
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Study design and evaluation
This study was an open-label, nonrandomized, multi-center 
phase I study of MK-0646 in patients with advanced colo-
rectal cancer (Fig. 1). All eligible patients were treated in 
either arm A, B, or C. The DLT assessment for the weekly 
(10 mg/kg) and every other week regimen (an initial dose 
of 15 mg/kg followed by a maintenance dose of 7.5 mg/kg) 
for the triple combination of MK-0646, cetuximab, and 
irinotecan in Japanese patients was conducted in arms 
A and B, respectively. The prespecified 4-week period of 
Cycle 1 was defined as the DLT evaluation period (arm 
A: Day 15–Day 42, arm B: Day 1–Day 28). Patients were 
enrolled in arm B in parallel with those in arm A using 
a 3 + 3 design. In arms A and B, if ≤2 of the first three 
patients developed a DLT, then three additional patients 
were enrolled at the same dose level. If all of the first 3 
patients developed a DLT, the enrollment of the additional 
Fig. 1  Study design
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3 patients in the arm was canceled. Enrollment in this study 
was sequential, not randomized. If 2 or less of the 6 patients 
manifested a DLT during the 4 weeks of Cycle 1 in arms A 
and B, the dosing regimen was considered tolerable.
Adverse events were graded using the National Can-
cer Institute Common Terminology Criteria for Adverse 
Events, version 3.0. DLT was defined as grade 4 neutrope-
nia lasting >5 days; grade 3 or 4 neutropenia with a fever 
>38.5 °C; grade 4 thrombocytopenia; or grade 3 or 4 non-
hematological toxicity, except for inadequately treated 
diarrhea, nausea and vomiting, rash, hyperglycemia, and 
transient electrolyte abnormalities. Anemia was not consid-
ered to be a DLT; patients were allowed blood transfusions 
as needed. Infusion reactions and hypersensitivity reactions 
were not considered to be DLTs.
Additionally, the dosing schedule for arm A was 
designed to assess the effect of MK-0646 on the PK param-
eters of cetuximab, irinotecan, and its metabolite (SN-38). 
The dosing schedule for arm C was designed to assess the 
effect of cetuximab and irinotecan on the PK parameters of 
MK-0646.
The anti-tumor activity was evaluated at baseline and 
every 6 weeks according to RECIST, version 1.0.
Pharmacokinetics
Blood samples for the measurement of the serum MK-0646 
concentration were collected on Day 1 and Day 22 of 
Cycle 1 in arm C (pre-dose, end of infusion, and 0.5, 5.0, 
8, 24, 48, 96, and 168 h after the start of infusion). The 
serum MK-0646 concentration was determined using a 
validated enzyme-linked immunosorbent assay (ELISA) 
with colorimetric detection at Tandem Labs. MK-0646 
was captured with immobilized recombinant human IGF-
1R and was detected using biotinylated mouse antihuman 
IgG1Fc, developed by the addition of streptavidin-HRP and 
TMB substrate. The calibration range of the assay was 20–
2,000 ng/mL in 100 % serum, with an LLOQ of 20 ng/mL.
Blood samples for the measurement of the serum cetuxi-
mab concentration were obtained on Day 15 and Day 29 
of Cycle 1 in arm A (pre-dose and 2.0, 5.0, 8.0, 24, 48, 96, 
and 168 h after the start of infusion). The serum cetuximab 
concentration was determined using a validated electro-
chemiluminescence (ECL) assay at Tandem Labs. Cetuxi-
mab was captured using biotinylated anti-cetuximab anti-
idiotype antibody and was detected with TAG-labeled 
anti-cetuximab anti-idiotype antibody. The calibration 
range of the assay was 3.91–250 ng/mL in 50 % serum, 
with an LLOQ of 7.8 ng/mL in 100 % serum.
Blood samples for the measurement of the plasma 
irinotecan concentrations were obtained on Day 15 and 
Day 29 of Cycle 1 in arm A (pre-dose and 1.0, 5.0, 8.0, 
24, and 48 h following the completion of the infusion). 
The plasma irinotecan and SN-38 concentrations were 
determined using validated LC-MS/MS methods at 
CEDRA Clinical Research LCC. The calibration range of 
the assays was 2–1,000 ng/mL for irinotecan and 1–500 ng/
mL for SN-38.
The MK-0646, cetuximab, irinotecan, and SN-38 PK 
parameters were determined using a noncompartment 
analysis and the serum or plasma concentrations of each 
analyte and the actual sampling times relative to the actual 
dose times. The AUC was natural log-transformed and 
analyzed using a linear mixed effects model, with fixed-
effect terms for treatment (with or without co-administered 
drugs). An unstructured covariance matrix was used to 
allow for unequal treatment variances and to model the cor-
relation between the two treatment measurements within 
each subject via the REPEATED statement in SAS PROC 
MIXED. Kenward and Roger’s method was used to cal-
culate the denominator degrees of freedom for the fixed 
effects (DDFM = KR). Exponentiating the least-squares 
means (mean differences) and the lower and upper limits of 
these confidence intervals yielded estimates for the popula-
tion geometric means (population geometric mean ratios) 
and confidence intervals for the geometric means (geomet-
ric mean ratios) on the original scale. A 95 % confidence 
interval (CI) was constructed for the geometric means of 
the AUCs for the treatment arms. To assess the effect of 
drug interactions, 90 % CI was constructed for the geomet-
ric mean ratios (GMRs) (with co-administered drugs vs. 
administration alone) of the AUC.
Immunogenicity
A sandwich format ELISA assay was developed for detect-
ing the incidence of human anti-humanized antibodies 
(HAHA) in response to MK-0646 therapy. The presence 
of HAHA was measured by analyzing sera collected from 
patients prior to the administration of the first dose of study 
medication, every 6 weeks during the study period, and 4, 




Twenty Japanese patients with advanced colorectal cancer 
were enrolled and were evaluated in this study. The baseline 
characteristics of the patients are summarized in Table 1. 
The age range was 51–71 years (median 61.5 years). Eight 
patients had colon cancer, and 12 patients had rectal can-
cer. The KRAS status was wild-type in 10 patients, mutant-
type in 7 patients, and unknown in 3 patients. The median 
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number of prior chemotherapy regimens was 3.0. Two 
patients enrolled in arm A were excluded from the DLT 
evaluation. One patient had grade 3 febrile neutropenia 
before the first administration of MK-0646, and this patient 
only received cetuximab and irinotecan. The other patient 
had grade 3 skin toxicity before the start of the DLT evalu-
ation period. Thus, two additional patients were enrolled in 
arm A (total of 8 patients). Six patients were treated in arms 
B and C, respectively. The median number of treatment 
cycles (1 cycle: 6 weeks) was 2.0 (range 1.0–3.0) in arm 
B, 2.0 (range 1.0–7.0) in arm B, and 2.5 (range 1.0–5.0) 
in arm C. The patients discontinued the study medication 
because of adverse events (n = 4), their physician’s deci-
sion (n = 1), progressive disease (n = 14), or the with-
drawal of consent (n = 1).
Safety and tolerability
Of the 6 patients who were evaluated for DLTs in arm A, 
none of the patients developed a DLT. Of the 6 patients 
who were evaluated for DLTs in arm B, one patient devel-
oped a DLT (grade 3 hyperglycemia). The time until the 
onset of the DLT after the administration of the study 
medication was 15 days, and the DLT resolved after the 
study medications were interrupted and treatment with an 
anti-hyperglycemic agent (pioglitazone) was initiated. The 
common drug-related adverse events reported for all the 
treatment cycles in all the arms are summarized in Table 2. 
The most common hematological adverse events related 
to the study medications (MK-0646 and/or cetuximab 
and/or irinotecan) included leukopenia (15/20; 75.0 %) 
and neutropenia (14/20; 70.0 %). The most common non-
hematological adverse events included dermatitis acnei-
form (13/20; 65.0 %), paronychia (13/20; 65.0 %), nau-
sea (12/20; 60.0 %), stomatitis (11/20; 55.0 %), diarrhea 
(11/20; 55.0 %), and decreased appetite (10/20; 50.0 %).
Pharmacokinetic evaluation
MK‑0646
The mean serum concentration profiles for MK-0646 after 
a 2-h IV infusion of 10 mg/kg of MK-0646 (arm C) are 
shown in Fig. 2. Descriptive statistics for the PK param-
eters are given in Table 3. The mean MK-0646 serum 
concentration after the co-administration of MK-0646 
with cetuximab/irinotecan during Week 4 (Day 22) 
was higher than that after MK-0646 administration 
Table 1  Baseline 










 Median 64.0 60.5 57.0 61.5
 Range 52–-68 53–62 51–71 51–71
Sex, n (%)
 Male 5 5 5 15
 Female 3 1 1 5
Weight (kg)
 Median 55.6 51.8 67.3 57.2
 Range 47.0–70.0 37.0–68.0 44.0–83.0 37.0–83.0
ECOG performance status, n (%)
 0 4 1 4 9
 1 4 5 2 11
Primary tumor, n (%)
 Colon cancer 3 3 2 8
 Rectal cancer 5 3 4 12
Stage of disease, n (%)
 IV 8 6 6 20
KRAS status
 Wild 4 3 3 10
 Mutant 4 2 1 7
 Unknown 0 1 2 3
Median no. of prior chemotherapy 2.5 4.0 2.0 3.0
 Range 2–3 2–6 2–5 2–6
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alone during Week 1 (Day 1). The arithmetic mean pre-
dose MK-0646 serum concentration during Week 4 was 
29.7 μg/mL, indicating the accumulation of MK-0646. 
The median time to reach Cmax (Tmax) was 5 h post-dose 
for the MK-0646 alone treatment and 3.5 h post-dose 
for the MK-0646 + cetuximab/irinotecan treatment. 
The exposure to MK-0646 upon co-administration with 
cetuximab and irinotecan during Week 4 was slightly 
higher than that when administered alone during Week 
1 (the geometric mean of the Cmax increased from 247.6 
to 311.9 μg/mL; the geometric mean of the AUC0–168h 
increased from 19.6 to 24.5 mg h/mL). The GMR and 
the 90 % CI of the AUC0–168h for the two treatments 
(MK-0646 + cetuximab/irinotecan vs. MK-0646 alone) 
were 1.25 and (1.15, 1.35).
Cetuximab
The mean serum concentration profiles for cetuximab after 
a 2-h IV infusion at 250 mg/m2 are shown in Fig. 2. The 
PK parameters are given in Table 4. The co-administration 
of MK-0646 with cetuximab/irinotecan produced a higher 
mean peak cetuximab concentration (geometric mean of 
the Cmax value of 236.5 vs. 204.0 μg/mL without MK-0646 
co-administration), which was reached earlier (median Tmax 
value of 2.0 vs. 7.9 h without MK-0646 co-administration). 
Table 2  Common adverse events related to study medications









All grades Grades 3–4 All grades Grades 3–4 All grades Grades 3–4 All grades Grades 3–4
Blood and lymphatic
System disorders
 Leukopenia 7 4 2 1 6 2 15 7
 Neutropenia 7 4 2 1 5 2 14 7
 Lymphopenia 4 2 0 0 3 1 7 3
 Thrombocytopenia 3 0 1 0 1 0 5 0
 Anemia 2 0 0 0 2 0 4 0
Skin and subcutaneous tissue disorders
 Dermatitis acneiform 7 3 1 0 5 2 13 5
 Dry skin 2 0 3 0 0 0 5 0
 Acne 0 0 4 0 0 0 4 0
 Alopecia 2 – 1 – 1 – 4 –
 Pruritus 2 0 2 0 0 0 4 0
Infections and infestations
 Paronychia 6 2 2 2 5 2 13 6
Gastrointestinal disorders
 Nausea 5 0 4 0 3 0 12 0
 Stomatitis 5 0 3 0 3 0 11 0
 Diarrhea 3 0 5 0 3 0 11 0
 Vomiting 1 0 2 0 3 0 6 0
 Constipation 1 0 2 0 2 0 5 0
Metabolism and nutrition disorder
 Decreased appetite 4 0 4 1 2 0 10 1
 Hyperglycemia 2 0 3 1 2 0 7 1
 Hypomagnesemia 2 0 2 1 3 1 7 2
 Hypoalbuminemia 3 0 1 0 1 0 5 0
General disorders
 Fatigue 4 1 4 0 1 0 9 1
 Pyrexia 1 0 1 0 2 0 4 0
Investigations
 Weight decreased 3 0 1 0 1 0 5 0
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The AUC of cetuximab was not altered by the co-adminis-
tration of MK-0646. The GMR of the cetuximab AUC0–168h 
(cetuximab + irinotecan + MK-0646/cetuximab + irinote-
can) was 1.07, with a 90 % CI of (0.94, 1.21), which was 
within the (0.80, 1.25) bioequivalence bounds.
Irinotecan/SN‑38
The mean plasma concentration profiles of irinotecan 
and SN-38 after a 30-min IV infusion at 150 mg/m2 are 
shown in Fig. 2. The PK parameters are given in Table 4. 
The mean irinotecan PK parameters with and without 
MK-0646 co-administration were comparable. The GMR 
of the irinotecan AUC0–24h was 0.95, with a 90 % CI of 
(0.90, 1.01), which was within the bioequivalence bounds 
(0.80, 1.25). The co-administration of MK-0646 with 
cetuximab/irinotecan reduced the peak SN-38 concentra-
tion (Cmax value of 13.0 vs. 16.8 ng/mL without MK-0646 
co-administration). The median Tmax was the same for both 
treatments (1.0 h). The SN-38 AUC was reduced after co-
administration with MK-0646 (126 vs. 157 ng h/mL), 
and the elimination half-life was increased upon the co-
administration of MK-0646 (19.4 vs. 12.8 h). The SN-38 
Nominal Time (hr)


























Arm C, Week 1 (MK-0646 only)
Arm C, Week 4 (MK-0646+
cetuximiab/irinotecan)
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Arm A, Week 3 (Cetuximab/irinotecan only)
Arm A, Week 5 (Cetuximab/irinotecan+
MK-0646)
Nominal Time (hr)



























Arm A, Day 15 (irinotecan/cetuximab only)
Arm A, Day 29 (irinotecan/cetuximab+MK-0646)
Nominal Time (hr)























Arm A, Day 15 (irinotecan/cetuximab only)
Arm A, Day 29 (irinotecan/cetuximab+MK-0646)
(a) (b)
(c) (d)
Fig. 2  Mean concentration versus time profiles for MK-0646 (a), cetuximab (b), irinotecan (c), and SN-38 (d)
Table 3  Pharmacokinetic parameters for MK-0646 following the 





 Geometric mean (coefficient of variation)
PK parameters Day 1 (n = 6)
MK-0646
Day 22 (n = 6)
Triple combination
Tmax (h)a 5.0 (2.0–8.0) 3.5 (2.0–24.0)
Ceoi (μg/mL)b 211.2 (14.3) 267.3 (27.1)
Cmax (μg/mL)b 247.6 (14.4) 311.9 (21.3)
t1/2 (h)b 131.4 (21.5) 141.4 (32.1)
CL (mL/min/kg)b 0.0049 (21.9) 0.0038 (33.7)
Vss (L/kg)b 0.0558 (11.1) 0.0459 (14.2)
AUC0–24h (mg h/mL)b 4.56 (11.7) 5.39 (18.8)
AUC0–168h (mg h/mL)b 19.6 (13.1) 24.5 (19.0)
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AUC0–24h GMR was 0.87, with a 90 % CI of (0.74, 1.01). 
The lower 90 % CI bound was outside the bioequivalence 
bounds (0.80, 1.25).
Antitumor activity
As an exploratory objective, the tumor response to the 
triple combination of MK-0646, cetuximab, and irinote-
can was evaluated according to the RESICT guidelines. 
Of the 20 patients whose response could be evaluated, 3 
patients achieved a partial response (3/20; 15.0 %) as the 
best response: one patient with colon cancer in arm B (the 
time to response was 37 days) and two patients with rectal 
cancer in arms B and C (the times to response were 33 and 
74 days, respectively). The KRAS status of the 3 respond-
ers was wild-type in 1 patient, mutant-type in 1 patient, and 
unknown in 1 patient. The duration of the response was 
250 days for the patient with rectal cancer in arm B, but 
this parameter was not calculated for the other two patients 
because these patients discontinued the treatment because 
of adverse events.
Immunogenicity evaluation
No HAHA was detected in the serum samples obtained 
throughout the study.
Discussion
The primary objective of this study was to evaluate the 
safety and tolerability of MK-0646 in combination with 
cetuximab irinotecan in Japanese patients with advanced 
colorectal cancer. Of the six patients who were evaluated 
for DLTs in arm A (MK-0646, 10 mg/kg weekly), none 
of the patients developed a DLT. Of the six patients who 
were evaluated for DLTs in arm B (MK-0646, 15 mg/kg 
as a loading dose followed by 7.5 mg/kg every 2 weeks), 
one patient developed a DLT (grade 3 hyperglycemia). 
The grade 3 hyperglycemia reported in this study was ade-
quately controlled with the interruption of MK-0646 treat-
ment and the administration of an oral anti-hyperglycemia 
agent; the patient was then able to continue the study medi-
cations with a reduced dose of MK-0646. In this study, 
hyperglycemia was reported in 7 (6 with grade 1–2, 1 with 
grade 3) of the 20 patients treated with the triple combina-
tion. Hyperglycemia is recognized as an adverse event of 
treatment with anti-IGF-1R antibodies [14]. In a previous 
study examining single-agent MK-0646 in non-Japanese 
patients, hyperglycemia that was thought to be treatment 
related was reported in 15 (14 with grade 1–2, 1 with grade 
3) of the 80 patients treated with MK-0646 [11]. The inci-
dence of hyperglycemia reported for the triple combination 
therapy was higher than that for the MK-0646 monother-
apy, but the small sample size of the present study prevents 
any definite conclusions from being made. The common 
treatment-related adverse events observed in this study 
included leukopenia, neutropenia, dermatitis acneiform, 
paronychia, nausea, stomatitis, diarrhea, and decreased 
appetite. These adverse events have also been reported for 
the single-agent uses of MK-0646, cetuximab, and irinote-
can. No significant increases in grade 3 or 4 adverse events 
were observed for the combination treatment, compared 
with monotherapy using each agent.
This is the first report of PK interactions for the combi-
nation of an anti-EGF-R antibody and an anti-IGF-1R anti-
body. The co-administration of cetuximab and irinotecan 
with MK-0646 increased the MK-0646 AUC0–168h by 25 %. 
As substantial pre-dose MK-0646 concentrations were 
observed before the co-administration treatment, MK-0646 
Table 4  Pharmacokinetic parameters for cetuximab, irinotecan, and SN-35 following the administration of cetuximab/irinotecan alone (Day 15) 




 Geometric mean (coefficient of variation)
PK parameters Cetuximab Irinotecan SN-38
Day 15 (n = 7)
Cetuximab/ 
irinotecan
Day 29 (n = 6)
Triple  
combination
Day 15 (n = 7)
Cetuximab/ 
irinotecan
Day 29 (n = 6)
Triple  
combination
Day 15 (n = 7)
Cetuximab/ 
irinotecan
Day 29 (n = 6)
Triple  
combination
Tmax (h)a 7.9 (2.0–8.0) 2.0 (2.0–2.1) 1.0 (0.97–1.0) 1.0 (1.0–1.1) 1.0 (0.97–5.0) 1.0 (1.0–1.1)
Cmax (μg/mL)b 204.0 (15.0) 236.5 (23.0) 1.21 (22.8) 1.13 (25.6) 0.0168 (33.8) 0.0130 (23.9)
t1/2 (h)b 129.4 (26.0) 131.9 (34.5) 8.95 (9.13) 9.67 (12.7) 12.8 (32.0) 19.4 (12.6)
AUC0–24h (μg h/mL)b 4,020 (14.5) 4,120 (26.1) 7.19 (33.6) 6.64 (31.9) 0.157 (51.1) 0.126 (21.3)
AUC0–168h (μg h/mL)b 18,600 (20.9) 20,100 (28.6) – – – –
CL (mL/h/m2)b 7.81 (32.8) 6.82 (40.5) 12,300 (35.7) 13,100 (34.3) – –
Vss (L/m2)b 1.45 (10.0) 1.32 (17.8) 117 (27.5) 137 (24.9) – –
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accumulation contributed to the observed increase in 
MK-0646 exposure during that treatment, and the increase 
in exposure could not be attributed entirely to the potential 
interactions of the co-administered drugs. The co-adminis-
tration of MK-0646 with cetuximab and irinotecan did not 
affect the PK of cetuximab and irinotecan. The GMR of 
the cetuximab AUC0–168h (cetuximab + irinotecan + MK-
0646/cetuximab + irinotecan) was 1.07, with a 90 % CI 
of (0.94, 1.21), which was within the bioequivalence 
bounds (0.80, 1.25). The co-administration of MK-0646 
with cetuximab and irinotecan reduced the Cmax and the 
AUC of SN-38. The SN-38 Cmax decreased from 16.8 to 
13.0 ng/mL upon MK-0646 co-administration, whereas 
the SN-38 AUC0–24h decreased by 13 %, with a 90 % CI 
of (0.74, 1.01). The PK interaction between cetuximab and 
irinotecan was previously assessed by Delbaldo et al. [15]. 
The results of that study showed an apparent decrease in 
the SN-38 Cmax and the AUC upon the co-administration 
of cetuximab and irinotecan; however, the difference was 
not statistically significant because of the large inter-sub-
ject variability, and the authors concluded that no PK inter-
action existed between the two drugs. The mean SN-38 
concentration-time profiles of the current study resembled 
those reported by Delbaldo et al. Since the irinotecan dos-
ing regimens (150 mg/m2/2 weeks in the current study vs. 
350 mg/m2/3 weeks in the Delbaldo et al. study) differed, 
a quantitative comparison of the profiles is not feasible. 
Taken together, these observations suggest that the co-
administration of MK-0646 with cetuximab and irinotecan 
had little effect, if any, on the PK of the three components 
of the combination.
The KRAS status has been reported to be a predictive 
marker of the response to cetuximab [16–18], but patients 
were enrolled in this study regardless of the KRAS status 
according to the Japanese package inserts for cetuximab 
at that time. Though the response rate was not the primary 
endpoint in this phase I study and was obtained from only a 
small number of patients, an add-on effect of MK-0646 was 
not observed; instead, the rate appeared to be lower (3/20; 
15.0 %) than historical data reported for the combination 
of cetuximab and irinotecan (22.9 % [9], 30.8 % [19]). No 
clear difference in the response rate between patients with 
the KRAS wild-type and those with the mutant-type was 
seen in this study. A randomized phase II/III study of the 
triple combination was conducted in patients with chemore-
fractory metastatic colorectal cancer with a wild-type KRAS 
status [20]. This phase II/III study was stopped at the first 
interim analysis because the addition of MK-0646 to cetuxi-
mab and irinotecan worsened the progression-free survival 
and overall survival. A comprehensive molecular analysis 
was undertaken retrospectively to identify possible predic-
tors of cetuximab resistance and MK-0646 response [21]. 
These data supported IGF-1 and IGF-2 as potential 
biomarkers for a response to MK-0646 therapy and a high 
IGF-1 level as a marker of resistance to cetuximab therapy. 
Further analyses in a molecularly selected population of 
metastatic colorectal cancer are underway.
A phase II study of IMC-A12, another anti-IGF-IR anti-
body, alone and in combination with cetuximab in patients 
with colorectal cancer refractory to EGFR inhibitor did 
not demonstrate meaningful anti-tumor activity [22]. Dis-
appointing results have also been reported for other anti-
IGF-1R antibodies in the treatment of non-small-cell lung 
cancer (NSCLC) [23, 24]. These study results underline the 
importance of identifying predictive biomarkers of IGF-
1R dependence in the development of future anti-IGF-IR 
antibodies.
In conclusion, the triple combination of MK-0646, 
cetuximab, and irinotecan was well tolerated in Japanese 
patients with advanced colorectal cancer. The present 
results indicated a minimal potential for PK interactions 
between MK-0646 and cetuximab and between MK-0646 
and irinotecan/SN-38.
Acknowledgments The authors would like to thank Jan A. M. 
Huisman (MSD Oss) for PK analysis, Shi Rong Han (MSD K.K.) for 
statistical analysis, and William D Hanley (Merck & Co., Inc.) for 
developing the study design. Research funding was provided by MSD 
K.K. (Tokyo, Japan).
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribu-
tion, and reproduction in any medium, provided the original author(s) 
and the source are credited.
References
 1. Saltz LB, Minsky B (2002) Adjuvant therapy of cancers of the 
colon and rectum. Surg Clin North Am 82:1035–1058
 2. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-
Mignard D et al (2004) FOLFIRI followed by FOLFOX6 or the 
reverse sequence in advanced colorectal cancer: a randomized 
GERCOR study. J Clin Oncol 22:229–237
 3. Czito BG, Hong TJ, Cohen DP, Tyler DS, Lee CG, Anscher MS 
et al (2004) A phase I trial of preoperative eniluracil plus 5-fluo-
rouracil and radiation for locally advanced or unresectable adeno-
carcinoma of the rectum and colon. Int J Radiat Oncol Biol Phys 
58:779–785
 4. Veronese ML, Sun W, Giantonio B, Berlin J, Shults J, Davis L 
et al (2005) A phase II trial of gefitinib with 5-fluorouracil, leuco-
vorin, and irinotecan in patients with colorectal cancer. Br J Can-
cer 92:1846–1849
 5. Cohen S (2004) Origins of growth factors: NGF and EGF. Ann 
NY Acad Sci 1038:98–102
 6. Resnick MB, Routhier J, Konkin T, Sabo E, Pricolo VE (2004) 
Epidermal growth factor receptor, c-MET, beta-catenin, and p53 
expression as prognostic indicators in stage II colon cancer: a tis-
sue microarray study. Clin Cancer Res 10:3069–3075
 7. Galizia G, Lieto E, Ferraraccio F, De Vita F, Castellano P, 
Orditura M et al (2006) Prognostic significance of epidermal 
growth factor receptor expression in colon cancer patients under-
going curative surgery. Ann Surg Oncol 13:823–835
652 Cancer Chemother Pharmacol (2013) 72:643–652
1 3
 8. Yasui W, Sumiyoshi H, Hata J, Kameda T, Ochiai A, Ito H et al 
(1988) Expression of epidermal growth factor receptor in human 
gastric and colonic carcinomas. Cancer Res 48:137–141
 9. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, 
Santoro A et al (2004) Cetuximab monotherapy and cetuximab 
plus irinotecan in irinotecan-refractory metastatic colorectal 
cancer. N Engl J Med 351:337–345
 10. Goetsch L, Gonzalez A, Leger O, Beck A, Pauwels PJ, Haeuw 
JF et al (2005) A recombinant humanized anti-insulin-like growth 
factor receptor type I antibody (h7C10) enhances the antitu-
mor activity of vinorelbine and anti-epidermal growth factor 
receptor therapy against human cancer xenografts. Int J Cancer 
113:316–328
 11. Adams TE, McKern NM, Ward CW (2004) Signalling by the 
type 1 insulin-like growth factor receptor: interplay with the epi-
dermal growth factor receptor. Growth Factors 22:89–95
 12. Atzori F, Tabernero J, Cervantes A, Prudkin L, Andreu J, Rod-
ríguez-Braun E et al (2011) A phase I pharmacokinetic and phar-
macodynamic study of dalotuzumab (MK-0646), an anti-insulin-
like growth factor-1 receptor monoclonal antibody, in patients 
with advanced solid tumors. Clin Cancer Res 17:6304–6312. 
doi:10.1158/1078-0432.CCR-10-3336
 13. Watkins DJ, Tabernero J, Schmoll HJ, Trarbach T, Ramos FJ, 
Hsu K et al (2009) A phase II study of the anti-IGFR antibody 
MK-0646 in combination with cetuximab and irinotecan in the 
treatment of chemorefractory metastatic colorectal cancer. J Clin 
Oncol 27(Supp 15):abstract 4127
 14. Weroha SJ, Haluska P (2008) IGF-1 receptor inhibitors in clinical 
trials—early lessons. J Mammary Gland Biol Neoplasia 13:471–
483. doi:10.1007/s10911-008-9104-6
 15. Delbaldo C, Pierga JY, Dieras V, Faivre S, Laurence V, Vedo-
vato JC et al (2005) Pharmacokinetic profile of cetuximab 
(Erbitux™) alone and in combination with irinotecan in patients 
with advanced EGFR-positive adenocarcinoma. Eur J Cancer 
41:1739–1745
 16. Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF et al 
(2006) KRAS mutation status is predictive of response to cetuxi-
mab therapy in colorectal cancer. Cancer Res 66:3992–3995
 17. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien 
CR, Makhson A et al (2009) Cetuximab and chemotherapy as 
initial treatment for metastatic colorectal cancer. N Engl J Med 
360:1408–1417. doi:10.1056/NEJMoa0805019
 18. Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, 
Tu D, Tebbutt NC et al (2008) K-ras mutations and benefit 
from cetuximab in advanced colorectal cancer. N Engl J Med 
359:1757–1765. doi:10.1056/NEJMoa0804385
 19. Tahara M, Shirao K, Boku N, Yamaguchi K, Komatsu Y, Inaba Y 
et al (2008) Multicenter phase II study of cetuximab plus irinote-
can in metastatic colorectal carcinoma refractory to irinotecan, 
oxaliplatin and fluoropyrimidines. Jpn J Clin Oncol 38:762–769. 
doi:10.1093/jjco/hyn102
 20. Watkins DJ, Tabernero J, Schmoll H, Trarbach T, Ramos FJ, 
Howe J et al (2011) A randomized phase II/III study of the anti-
IGF-1R antibody MK-0646 (dalotuzumab) in combination with 
cetuximab (Cx) and irinotecan (Ir) in the treatment of chemore-
fractory metastatic colorectal cancer (mCRC) with wild-type (wt) 
KRAS status. J Clin Oncol 29(Suppl):abstract 3501
 21. Watkins DJ, Ayers M, Cunningham D, Tabernero J, Tejpar S, 
Kim TY et al (2012) Molecular analysis of the randomized phase 
II/III study of the anti-IGF-1R antibody dalotuzumab (MK-0646) 
in combination with cetuximab (Cx) and irinotecan (Ir) in the 
treatment of chemorefractory KRAS wild-type metastatic colo-
rectal cancer (mCRC). J Clin Oncol 30(Suppl):abstract 3531
 22. Reidy DL, Vakiani E, Fakih MG, Saif MW, Hecht JR, Goodman-
Davis N et al (2010) Randomized, phase II study of the insulin-
like growth factor-1 receptor inhibitor IMC-A12, with or without 
cetuximab, in patients with cetuximab- or panitumumab-refrac-
tory metastatic colorectal cancer. J Clin Oncol 28:4240–4246. doi: 
10.1200/JCO.2010.30.4154
 23. Ramalingam SS, Spigel DR, Chen D, Steins MB, Engelman JA, 
Schneider CP et al (2011) Randomized phase II study of erlotinib 
in combination with placebo or R1507, a monoclonal antibody 
to insulin-like growth factor-1 receptor, for advanced-stage non-
small-cell lung cancer. J Clin Oncol 29:4574–4580. doi:10.1200/
JCO.2011.36.6799
 24. Jassem J, Langer CJ, Karp DD, Mok T, Benner RJ, Green SJ et al 
(2010) Randomized, open label, phase III trial of figitumumab in 
combination with paclitaxel and carboplatin versus paclitaxel and 
carboplatin in patients with non-small cell lung cancer (NSCLC). 
J Clin Oncol 28(Suppl 15):abstract 7500
